Cross-talk between ribosome biogenesis, translation, and mTOR in CD133+4/CD44+prostate cancer stem cells

Basit Öğe Kaydı
dc.contributor.authorBinal, Z.
dc.contributor.authorAcikgoz, E.
dc.contributor.authorKizilay, F.
dc.contributor.authorOktem, G.
dc.contributor.authorAltay, B.
dc.date.accessioned2020-12-01T12:09:05Z
dc.date.available2020-12-01T12:09:05Z
dc.date.issued2020
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective To investigate the gene expression profile of CSCs and to explore the key pathways and specific molecular signatures involved in the characteristic of CSCs. Materials and methods CD133+ /CD44+ CSCs and bulk population (non-CSCs) were isolated from DU-145 cells using fluorescence-activated cell sorting (FACS). We used Illumina HumanHT-12 v4 Expression to investigate gene expression profiling of CSCs and non-CSCs. Protein-protein interaction (PPI) network analysis was performed using the STRING database. Biomarkers selected based on gene expression profiling were visually analyzed using immunofluorescence staining method. An image analysis program, ImageJ (R), was used for the analysis of fluorescence intensity. Results in microarray analysis, we found that many ribosomal proteins and translation initiation factors that constitute the mTOR complex were highly expressed. PPI analysis using the 33 genes demonstrated that there was a close interaction between ribosome biogenesis, translation, and mTOR signaling. the fluorescence amount of mTOR and MLST8 were higher in CSCs compared to non-CSCs. Conclusions the increase in a number of genes associated with ribosome biogenesis, translation, and mTOR signaling may be important to evaluate prognosis and determine treatment approach for prostate cancer (PCa). A better understanding of the molecular pathways associated with CSCs may be promising to develop targeted therapies to prolong survival in PCa.en_US
dc.identifier.doi10.1007/s12094-019-02229-1en_US
dc.identifier.endpage1048en_US
dc.identifier.issn1699-048X
dc.identifier.issn1699-3055
dc.identifier.issue7en_US
dc.identifier.pmid31630355en_US
dc.identifier.scopus2-s2.0-85074250947en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1040en_US
dc.identifier.urihttps://doi.org/10.1007/s12094-019-02229-1
dc.identifier.urihttps://hdl.handle.net/11454/63294
dc.identifier.volume22en_US
dc.identifier.wosWOS:000491662000001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer International Publishing Agen_US
dc.relation.ispartofClinical & Translational Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectProstate canceren_US
dc.subjectCancer stem cellen_US
dc.subjectRibosomal proteinsen_US
dc.subjectTranslationen_US
dc.subjectmTORen_US
dc.titleCross-talk between ribosome biogenesis, translation, and mTOR in CD133+4/CD44+prostate cancer stem cellsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu